Investors Should Watch: Array BioPharma, Inc. (NASDAQ:ARRY), Comcast Corporation (NASDAQ:CMCSA), Tech Data Corp. (NASDAQ:TECD), Worthington Industries, Inc. (NYSE:WOR), LDR Holding Corporation (NASDAQ:LDRH)

On Dec 12, Oncothyreon Inc. announced that Array BioPharma, Inc. (NASDAQ:ARRY) has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor. The license agreement replaces the prior Development and Collaboration Agreement under which Oncothyreon and Array were jointly developing ONT-380. Array BioPharma,…

Read More

Why Need to Watch: Array BioPharma, Inc. (NASDAQ:ARRY), Hewlett-Packard Company (NYSE:HPQ), Polycom, Inc. (NASDAQ:PLCM), Endurance International Group (NASDAQ:EIGI), Diamond Offshore Drilling (NYSE:DO)

Array BioPharma, Inc. (NASDAQ:ARRY) announced that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC on April 22, 2014, which are expected in…

Read More
Home